Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options
AbstractMolecular testing is performed upon diagnosis of non-small cell lung cancer (NSCLC) because of the large success of targeted therapies for oncogenic mutations. Epidermal growth factor receptor (EGFR) mutations are the most commonly identified mutation in NSCLC, andEGFR exon 20 insertion mutations (exon20ins) are the third most common mutation inEGFR followingEGFR exon 19 deletions and exon 21 L858R mutations.EGFR exon20ins have regularly demonstrated resistance to classical EGFR inhibition. Two treatments —mobocertinib and amivantamab—have recently been the first drugs to be approved by the US Food and Drug Ad...
Source: BioDrugs - October 18, 2022 Category: Drugs & Pharmacology Source Type: research
Correction: Immunotherapy in Gastro-Oesophageal Cancer: Current Practice and the Future of Personalised Therapy
(Source: BioDrugs)
Source: BioDrugs - October 15, 2022 Category: Drugs & Pharmacology Source Type: research
Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial
ConclusionsEquivalent efficacy and similar pharmacokinetics, safety, and immunogenicity support bioequivalence of CT-P16 and EU-bevacizumab in patients with nsNSCLC.Trial registration numberNCT03676192. (Source: BioDrugs)
Source: BioDrugs - September 28, 2022 Category: Drugs & Pharmacology Source Type: research
The Economic Burden of CAR T Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US
ConclusionThis study found that the CAR T cell gene therapies ciltacabtagene autoleucel and idecabtagene vicleucel for rrMM represent a significant economic burden for healthcare payers in the USA. (Source: BioDrugs)
Source: BioDrugs - September 27, 2022 Category: Drugs & Pharmacology Source Type: research
Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (Novolog ®) in Patients with Type 1 Diabetes After 24 Weeks: A Randomized Open-Label Study
ConclusionsMYL-1601D demonstrated similar immunogenicity, efficacy, and safety profiles to Ref-InsAsp-US in patients with T1D over 24 weeks.Clinical Trial Registration ClinicalTrials.gov:NCT03760068. (Source: BioDrugs)
Source: BioDrugs - September 17, 2022 Category: Drugs & Pharmacology Source Type: research
PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras
AbstractIn the recent past, proteolysis-targeting chimera (PROTAC) technology has received enormous attention for its ability to overcome the limitations of protein inhibitors and its capability to target undruggable proteins. The PROTAC molecule consists of three components, a ubiquitin E3 ligase ligand, a linker, and a target protein ligand. The application of this technology is rapidly gaining momentum, especially in cancer therapy. In this review, we first look at the history of degraders, followed by a section on the ubiquitin proteasome system (UPS) and E3 ligases used in PROTAC development. PROTACs are dependent on ...
Source: BioDrugs - September 13, 2022 Category: Drugs & Pharmacology Source Type: research
Teserpaturev/G47 Δ: First Approval
This article summarizes the milestones in the develo pment of teserpaturev/G47Δ leading to this first approval for the treatment of malignant glioma. (Source: BioDrugs)
Source: BioDrugs - September 13, 2022 Category: Drugs & Pharmacology Source Type: research
PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras
AbstractIn the recent past, proteolysis-targeting chimera (PROTAC) technology has received enormous attention for its ability to overcome the limitations of protein inhibitors and its capability to target undruggable proteins. The PROTAC molecule consists of three components, a ubiquitin E3 ligase ligand, a linker, and a target protein ligand. The application of this technology is rapidly gaining momentum, especially in cancer therapy. In this review, we first look at the history of degraders, followed by a section on the ubiquitin proteasome system (UPS) and E3 ligases used in PROTAC development. PROTACs are dependent on ...
Source: BioDrugs - September 13, 2022 Category: Drugs & Pharmacology Source Type: research
